

# Metastatic Disease

## Brain Mets

HER 2 Positive Breast CA Pri.

Excluding germ cell, small cell, unknown primary, lymphoma, LMD

\* $\geq 1$  measurable, unirradiated brain met (no more than 10)  
 \*minimum size: single lesion  $\geq 10$ mm;  $\geq 2$  lesions the size of 2 must be  $\geq 5$ mm  
**OR**  
 Prior SRS or resection for 1-3 brain mets with  $\geq 1$  new measurable brain met

\*Brain Mets outside a 5-mm margin around either hippocampus on MRI  
 \*Must have had a SPGR, MP-RAGE, or TFE MRI  
 \*KPS  $\geq 70$

**RTOG 1119 - Phase II Randomized Study of Whole Brain Radiotherapy with Concurrent Lapatinib**

**NRG CC001- Memantine Hydrochloride and Whole-Brain RT +/- Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients W/Brain Mets**

[Schema](#)  
[Protocol Information-](#)  
 link to clinicaltrials.gov

[Schema](#)  
[Protocol Information-](#)  
 link to clinicaltrials.gov

## Oligometastases

Breast Cancer (path confirmed mets w/in 365 days)

Breast, NSLC, Adenocarcinoma of Prostate,  $\leq 4$  mets amenable to SBRT

\* $\leq 4$  metastases on standard imaging when all mets are located in peripheral lung, bone and spine  
 \* $\leq 2$  mets on standard imaging when any one met is located in: liver, central lung, mediastinal/cervical LN, abd/pelvic metastasis  
 \*Controlled primary tumor (defined by definitive surgery +/- radiotherapy for the primary tumor).  
 \*All known disease amenable to metastasis directed therapy with SBRT or Surgery  
 \*Max diameter of individual mets  $\leq 5$  cm

**The sites of allowed metastases are:** peripheral lung, central lung, mediastinal/cervical lymph node, liver, spinal/paraspinal, osseous, and abdominal/pelvic  
**Have 1 of the Following:**  
 \* 3-4 distinct mets of any distribution in the allowed anatomical sites  
 \* 2 distinct mets that must be with  $\leq 5$ cm of normal tissue between them  
 \* 3-4 distinct mets, 2-3 to be treated with SBRT and the other (s) having been surgically removed

**NRG-BR002 - Phase IIR/III Trial of Standard of Care Therapy +/- Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer**

**NRG BR001 - Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases**

[Schema](#)  
[Protocol Information-](#)  
 link to clinicaltrials.gov

[Schema](#)  
[Protocol Information-](#)  
 link to clinicaltrials.gov